Fixed dose combinations of an Organic Anion Transporter Polypeptide activator with a statin drug to reduce statin induced myopathy KU Leuven
The goal of the project is to enable statin-based therapy with a superior safety profile as compared to existing statin based dosing regimens. Our hypothesis is that the combination of an OATP activator with a statin will lead to higher statin levels in the liver. Due to lower systemic statin levels, myopathy will be reduced and patients can be treated for a longer period of time with statins.
A number of compounds such as domperidone, ...